SCHEDULE: Johnson & Johnson Maintains 15.4% Stake in CVRx
Beneficial Ownership Report
Johnson & Johnson and its subsidiary JJDC, Inc. have filed an amendment to their Schedule 13G, confirming a 15.4% beneficial ownership in CVRx, Inc.
Summary
- Johnson & Johnson (J&J) and its wholly-owned subsidiary, Johnson & Johnson Innovation JJDC, Inc. (JJDC), jointly filed Amendment No. 3 to Schedule 13G.
- The filing reports beneficial ownership of 4,024,861 shares of CVRx, Inc. Common Stock.
- This represents 15.4% of CVRx, Inc.'s outstanding Common Stock.
- The percentage ownership is based on 26,210,109 shares of Common Stock outstanding as of October 30, 2025, as reported in CVRx, Inc.'s Form 10-Q for the period ended September 30, 2025.
- Both J&J and JJDC share voting and dispositive power over these 4,024,861 shares.
- This amendment updates previous filings from February 7, 2022, February 2, 2024, and November 1, 2024.
Sentiment
Score: 5
Explanation: The filing is a routine regulatory update on beneficial ownership, providing factual information without expressing positive or negative sentiment.
Future Outlook
The filing does not contain any forward-looking statements or guidance.
Industry Context
This filing indicates a continued significant investment by a major healthcare conglomerate, Johnson & Johnson, in CVRx, Inc., a company operating in the medical device sector. Such sustained ownership by a strategic investor can signal confidence in the smaller company's technology or market position within the broader healthcare industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming continued investment by Johnson & Johnson.
Key Dates
| Date | Description |
|---|---|
| 2022-02-07 | Initial Schedule 13G filing by Reporting Persons. |
| 2024-02-02 | Amendment No. 1 to Schedule 13G filed. |
| 2024-11-01 | Amendment No. 2 to Schedule 13G filed. |
| 2025-09-30 | End of period for CVRx, Inc.'s Report on Form 10-Q, which reported shares outstanding. |
| 2025-10-30 | Date as of which 26,210,109 shares of Common Stock were outstanding for CVRx, Inc. |
| 2025-11-06 | Date CVRx, Inc. filed its Report on Form 10-Q for the period ended September 30, 2025. |
| 2025-12-31 | Date of event which requires filing of this statement. |
| 2026-01-12 | Signature date of the current Amendment No. 3 to Schedule 13G. |
Keywords
CVRx Inc, Johnson & Johnson, JJDC Inc, Schedule 13G, Beneficial Ownership, Common Stock, Medical Devices, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.